Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 861

1.

Identification of isoform-selective hydroxamic acid derivatives that potently reactivate HIV from latency.

Heffern EF, Ramani R, Marshall G, Kyei GB.

J Virus Erad. 2019 Apr 1;5(2):84-91.

PMID:
31191911
2.

Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment.

Relaño-Rodríguez I, Juárez-Sánchez R, Pavicic C, Muñoz E, Muñoz-Fernández MÁ.

J Nanobiotechnology. 2019 May 21;17(1):69. doi: 10.1186/s12951-019-0500-4.

3.

Bryostatin-1 inhibits cell proliferation of hepatocarcinoma and induces cell cycle arrest by activation of GSK3β.

Wang J, Wang Z, Sun Y, Liu D.

Biochem Biophys Res Commun. 2019 May 7;512(3):473-478. doi: 10.1016/j.bbrc.2019.03.014. Epub 2019 Mar 20.

PMID:
30904158
4.

Cancer Biomarkers for Integrative Oncology.

Ganguly A, Frank D, Kumar N, Cheng YC, Chu E.

Curr Oncol Rep. 2019 Mar 5;21(4):32. doi: 10.1007/s11912-019-0782-6. Review.

PMID:
30834992
5.

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals.

Fromentin R, DaFonseca S, Costiniuk CT, El-Far M, Procopio FA, Hecht FM, Hoh R, Deeks SG, Hazuda DJ, Lewin SR, Routy JP, Sékaly RP, Chomont N.

Nat Commun. 2019 Feb 18;10(1):814. doi: 10.1038/s41467-019-08798-7.

6.

Towards 20,20-difluorinated bryostatin: synthesis and biological evaluation of C17,C27-fragments.

Mears PR, Hoekman S, Rye CE, Bailey FP, Byrne DP, Eyers PA, Thomas EJ.

Org Biomol Chem. 2019 Feb 6;17(6):1487-1505. doi: 10.1039/c8ob03152e.

PMID:
30681118
7.

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease.

Farlow MR, Thompson RE, Wei LJ, Tuchman AJ, Grenier E, Crockford D, Wilke S, Benison J, Alkon DL.

J Alzheimers Dis. 2019;67(2):555-570. doi: 10.3233/JAD-180759.

8.

T cell toxicity of HIV latency reversing agents.

Zhao M, De Crignis E, Rokx C, Verbon A, van Gelder T, Mahmoudi T, Katsikis PD, Mueller YM.

Pharmacol Res. 2019 Jan;139:524-534. doi: 10.1016/j.phrs.2018.10.023. Epub 2018 Oct 23.

PMID:
30366100
9.

RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency.

Méndez C, Ledger S, Petoumenos K, Ahlenstiel C, Kelleher AD.

Retrovirology. 2018 Oct 4;15(1):67. doi: 10.1186/s12977-018-0451-0.

10.

Tumor cell density regulates matrix metalloproteinases for enhanced migration.

Jayatilaka H, Umanzor FG, Shah V, Meirson T, Russo G, Starich B, Tyle P, Lee JSH, Khatau S, Gil-Henn H, Wirtz D.

Oncotarget. 2018 Aug 24;9(66):32556-32569. doi: 10.18632/oncotarget.25863. eCollection 2018 Aug 24.

11.

Diversity and Dynamics of "Candidatus Endobugula" and Other Symbiotic Bacteria in Chinese Populations of the Bryozoan, Bugula neritina.

Li H, Mishra M, Ding S, Miyamoto MM.

Microb Ecol. 2019 Jan;77(1):243-256. doi: 10.1007/s00248-018-1233-x. Epub 2018 Aug 23.

PMID:
30141128
12.

Protein kinase C -activating isophthalate derivatives mitigate Alzheimer's disease-related cellular alterations.

Sarajärvi T, Jäntti M, Paldanius KMA, Natunen T, Wu JC, Mäkinen P, Tarvainen I, Tuominen RK, Talman V, Hiltunen M.

Neuropharmacology. 2018 Oct;141:76-88. doi: 10.1016/j.neuropharm.2018.08.020. Epub 2018 Aug 21.

PMID:
30138694
13.

In Vitro Exposure to Prostratin but Not Bryostatin-1 Improves Natural Killer Cell Functions Including Killing of CD4+ T Cells Harboring Reactivated Human Immunodeficiency Virus.

Desimio MG, Giuliani E, Ferraro AS, Adorno G, Doria M.

Front Immunol. 2018 Jun 29;9:1514. doi: 10.3389/fimmu.2018.01514. eCollection 2018.

14.

Inhibition of Inflammation, Suppression of Matrix Metalloproteinases, Induction of Neurogenesis, and Antioxidant Property Make Bryostatin-1 a Therapeutic Choice for Multiple Sclerosis.

Safaeinejad F, Bahrami S, Redl H, Niknejad H.

Front Pharmacol. 2018 Jun 19;9:625. doi: 10.3389/fphar.2018.00625. eCollection 2018.

15.

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.

Marsden MD, Wu X, Navab SM, Loy BA, Schrier AJ, DeChristopher BA, Shimizu AJ, Hardman CT, Ho S, Ramirez CM, Wender PA, Zack JA.

Virology. 2018 Jul;520:83-93. doi: 10.1016/j.virol.2018.05.006. Epub 2018 May 26.

16.

Review of bioactive secondary metabolites from marine bryozoans in the progress of new drugs discovery.

Tian XR, Tang HF, Tian XL, Hu JJ, Huang LL, Gustafson KR.

Future Med Chem. 2018 Jun 1;10(12):1497-1514. doi: 10.4155/fmc-2018-0012. Epub 2018 May 23. Review.

17.

Chemoenzymatic Dissection of Polyketide β-Branching in the Bryostatin Pathway.

Slocum ST, Lowell AN, Tripathi A, Shende VV, Smith JL, Sherman DH.

Methods Enzymol. 2018;604:207-236. doi: 10.1016/bs.mie.2018.01.034. Epub 2018 Apr 9.

18.

Loss in PKC Epsilon Causes Downregulation of MnSOD and BDNF Expression in Neurons of Alzheimer's Disease Hippocampus.

Sen A, Nelson TJ, Alkon DL, Hongpaisan J.

J Alzheimers Dis. 2018;63(3):1173-1189. doi: 10.3233/JAD-171008.

PMID:
29710707
19.

Protein kinase C activator bryostatin-1 modulates proteasome function.

Khan TK, Nelson TJ.

J Cell Biochem. 2018 Aug;119(8):6894-6904. doi: 10.1002/jcb.26887. Epub 2018 Apr 25.

PMID:
29693282
20.

Exposure to far-infrared rays attenuates methamphetamine-induced recognition memory impairment via modulation of the muscarinic M1 receptor, Nrf2, and PKC.

Mai HN, Sharma N, Shin EJ, Nguyen BT, Nguyen PT, Jeong JH, Jang CG, Cho EH, Nah SY, Kim NH, Nabeshima T, Kim HC.

Neurochem Int. 2018 Jun;116:63-76. doi: 10.1016/j.neuint.2018.03.009. Epub 2018 Mar 20.

PMID:
29572053

Supplemental Content

Loading ...
Support Center